|
On november 14, 2023, the spanish subsidiary notified us of an adverse event following the use of teosyal rha 4 in a patient.A patient was injected on (b)(6) 2023, with 0.5 ml of teosyal rha 4 in the right cheek.The injection was done with a cannula using the retrotracing technique.According to the medical history of the patient, she was injected with teosyal rha 4 in 2018 in the zygomatic area and the nasolabial folds, without presenting with any adverse reactions.Immediately after the injection, on (b)(6) 2023, the patient experienced a mild vascular compromise, as she presented with delayed capillary refill in the injected area.On the same day, the injector administered 3 cycles of hyaluronidase (2000 iu in total) to the patient in one hour and a half.On november 14, 2023, we were informed that the patient had completely recovered.Thus, this case was considered closed.
|
|
Vascular complications are rare and serious side effects, although they are widely known and documented in the context of dermal filler injections.They are related to the accidental injection of the product inside a blood vessel, leading to its occlusion.The local deprivation of blood supply causes tissue anoxia.If enough hyaluronidase is injected on time, symptoms can be fully resolved without sequalae.If the vascular complication is not detected, diagnosed, and treated promptly, it can lead to skin necrosis.The risk of such adverse reactions is mentioned in the instructions for use of teosyal products.
|